We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GSK Gsk Plc

0.00 (0.00%)
15 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Gsk Plc GSK London Ordinary Share
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 1,643.50 16:35:05
Open Price Low Price High Price Close Price Previous Close
1,638.50 1,631.00 1,648.00 1,643.50 1,643.50
more quote information »
Industry Sector

Gsk GSK Dividends History

Announcement Date Type Currency Dividend Amount Ex Date Record Date Payment Date

Top Dividend Posts

Top Posts
Posted at 03/4/2024 08:21 by geckotheglorious
GSK picking up momentum, says HL’s Clayton
GSK (GSK) is ‘fighting back into contention’ with a bumper crop of new product launches in the pipeline, says Hargreaves Lansdown manager Steve Clayton.

Clayton holds the Citywire Elite Companies AAA-rated pharmaceutical giant in his HL Select UK Income Shares fund, where it makes up 3% of the £138m portfolio.

The group has been focused on restructuring, with a spin out of its consumer division Haleon (HLN), and developing new medicines such as shingles vaccine Shingrix, which Clayton said is ‘already a multi-billion dollars a year product’.

The arrival of US activist investors Elliott Management a few years ago highlighted ‘the weak returns GSK had achieved, despite some real clinical strengths within the business’.

‘The company is now more optimistic about its research pipeline delivering more meaningful new drugs than for many years,’ Clayton said.

‘GSK’s business has more clarity about it these days and its current pipeline of 71 assets is predicted by GSK to contain at least 12 major new products to be launched from 2025 onwards.’

The shares dropped 2.5% to £16.65 on Tuesday, but have added almost 16% over the last 12 months.
Posted at 04/3/2024 07:46 by pj84
JOHCM’s Costar views GSK as a good pick
GSK (GSK) is ‘attractively valued’ versus its pharmaceutical peers even though it has addressed profitability concerns, says JOHCM manager Mark Costar.

The Citywire Elite Companies AAA-rated stock is the second-largest holding in the JOHCM UK Dynamic fund, where it makes up 5.5% of the £1bn portfolio. Costar took over the running of the fund in January following the departure of Alex Savvides who left for Jupiter.

GSK was the second-largest contributor to returns in January after it reported ‘an encouraging set of full-year 2023 annual results while upgrading long-term growth guidance’.

It also addressed concerns about the ‘patent loss cliff edge’ suffered by its Dolutegravir HIV treatment and ‘its potential impacts on future profitability’.

‘Encouragingly, the fourth-quarter dividend was also increased, a step towards better shareholder returns where the fund has been engaged,’ said Costar.

‘The shares remain attractively valued versus peers, with further positive runway should a resolution to the Zantac case materialise.’

The shares softened 0.2% to £16.62 on Friday.
Posted at 13/2/2024 10:09 by tradermichael
The healthcare team at Citi has turned positive on GSK PLC (LSE:GSK, NYSE:GSK) for the first time in seven years.

Pushing the investment bank's analysts over the precipice to 'buy' was the outlook for belantamab mafodotin, (known as Blenrep for short), the drug giant's treatment for the blood disease myeloma.

"Our upgrade is based not only on Blenrep’s underappreciated revenue potential but also the cumulative impact of the multiple incremental positives ranging from Zantac liability outlook, RSV/ Shingrix, astute business development, and increasingly positive ViiV outlook post dolutegravir loss of exclusivity," Citi said in a note to clients.

Its upbeat stance on Blenrep stems from the "compelling" results from GSK's DREAMM-7 phase III clinical trial. Assuming the next set of study results are positive, then the drug "has a significant role for at least the next five years as a standard of care for refractory myeloma patients, particularly for older patients that are either poor candidates for CAR-T or bispecifics, or who receive their treatment within the community".

In early trade, the shares were up 14.34p at 1,640.74p. Citi reckons the stock is worth £21 (up from £17).
Posted at 09/2/2024 09:21 by tradermichael
Alector, Inc. (Nasdaq: ALEC) and GSK plc (LSE/NYSE: GSK) today announced that the first patient has been dosed in PROGRESS-AD, the global Phase 2 clinical trial of AL101/GSK4527226 in patients with early Alzheimer’s disease (AD), including mild cognitive impairment and mild dementia due to AD. AL101 is an investigational human monoclonal antibody designed to block and downregulate the sortilin receptor to elevate the level of progranulin in the brain in a manner similar to investigational latozinemab but with different pharmacokinetic (PK) and pharmacodynamic (PD) properties. Alector and GSK are co-developing and will be co-commercializing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson’s disease.
Posted at 07/2/2024 21:09 by pj84
From yesterdays questor column

"GSK is performing well despite the legal clouds that hang over it
Questor share tip: more of its vaccines are proving their worth and the company’s valuation fails to reflect punchy growth forecasts

Russ Mould

6 February 2024 • 6:00am

Strong full-year numbers last week, a planned dividend rise in 2024 and upgraded medium-term growth and profit forecasts all support our confidence in GSK, where a blossoming drugs pipeline gives additional visibility and increases the chances of some reward for readers in the form of both capital appreciation and income.

A fourth dismissal or settlement of lawsuits relating to the heartburn treatment Zantac is also encouraging.

While the legal cloud regarding the drug and its allegedly carcinogenic side-effects is far from fully lifted, the market’s worst fears regarding possible liabilities are yet to be borne out and the shares still trade some 9pc below highs reached almost two years ago.

GSK still faces a lengthy list of cases, but the more that are settled, the greater the chance that investors can again focus on the day-to-day business, which is performing well.

The launch of the respiratory syncytial virus vaccine Arexvy is going well, judging by 2023’s sales tally of £1.2bn, which is already 4pc of the group total.

That nicely supplements the £3.4bn revenues from shingles vaccine Shingrix and helps the company to get over its embarrassing failure to match Pfizer, Moderna and AstraZeneca in the race to find a Covid vaccine.

GSK now has 71 vaccines and speciality medicines in its drug development pipeline, including 18 at the Phase III stage, and is hoping for a dozen to come to market from 2025 onwards in areas such as HIV, oncology and respiratory conditions.

This roadmap presumably underpins the upgrade to medium-term sales and profits growth targets offered by chief executive Dame Emma Walmsley alongside the full-year figures.

GSK now expects compound annual growth rates of 7pc in revenues and 11pc in earnings between 2021 and 2026. Such a rate of progress would suggest that a multiple of barely 12 times forecast earnings looks decent value, especially when it is supported by a yield of 3.6pc, based on management’s guidance for a 60p-a-share dividend in 2024.

GSK still looks like good value. Hold."
Posted at 11/1/2024 10:11 by anhar
MHRANGOON is correct that you have to adjust for the consolidation in order to compare current values with the pre-demerger value. You can't just look at the share prices alone to make a comparison with the pre-demerger value, you need to consider the number of shares involved.

The terms were that pre-demerger GSK holders received 1 HLN for every 1 GSK share held. Following that, GSK shares were consolidated at 4 for 5.

So assume for example you held 1,000 old GSK, then you would now have 1,000 HLN and 800 current GSK.

Using the above figures, the old GSK share price of 1,800p gives a value of £18,000 pre-dem.

With new GSK now at 1,570p the holding is worth £12,560 and HLN £3,370, a total of £15,930 which is a loss of £2,070 or 11.5% on the old GSK value. Clearly then, the combined holding would have to rise to £18,000 just to break even, which could be satisfied by GSK or HLN alone or some combination of the two.
Posted at 24/12/2023 15:47 by pj84
Some snippets from the Sunday Times article: -

"GSK plans deal spree to boost drug pipeline

The pharmaceuticals giant GSK is set for a multibillion-pound buying spree of respiratory businesses as it seeks to reassure investors about its lacklustre pipeline, according to the man many see as heir to the chief executive’s throne."


"GSK will partially finance its buying spree with the cash generated by selling down its stake in Haleon, the consumer health firm behind Sensodyne toothpaste, that GSK spun off last year. In October, it raised about £900 million by selling down another chunk of its stake; it currently holds about 7 per cent of Haleon.

Miels ruled out deals in the “tens of billions” of dollars and said GSK was more focused on “very targeted single products or two products in a company”.

He added: “I think top priority is respiratory and auto-immune, [but]… we’re very busy across the board.”"
Posted at 17/10/2023 18:39 by pj84
From the above:-


"The board now expects GSK to generate sales growth of between 8pc and 10pc and adjusted operating profit and earnings per share growth in the range of 11pc to 13pc and 14pc to 17pc respectively. On each occasion GSK nudged up growth estimates by a couple of percentage points."


"GSK’s aim is to double sales of Shingrix to £4bn by 2026 and last week’s exclusive strategic agreement with China’s largest vaccine firm, Chongqing Zhifei Biological Products, to co-promote the product is a big step in that direction."


"Yet GSK trades at barely 11 times forecast earnings, with a dividend yield near 4pc. The earnings multiple represents a clear discount to rivals such as AstraZeneca, Switzerland’s Roche, tipped yesterday in this column’s online version, and America’s Bristol-Myers Squibb, which trade on 30, 15 and 14 times earnings respectively.

The shares would also look cheap were GSK to meet its own long-term growth targets, reaffirmed alongside the interim results. It is committed to generating compound trend sales growth of more than 5pc a year and compound adjusted operating profit growth of more than 10pc a year, as profit margins expand from the 30pc recorded in the first six months of 2023.

GSK could look cheap as and when the legal clouds lift."
Posted at 05/10/2023 10:07 by tradermichael
Nice HLN dividend payment received this morning. Followed by GSK dividend next week.

Next xd for GSK is 16 Nov ..... ;0)
Posted at 29/8/2023 10:23 by anhar
POR: What slashed divi?

Afaiaa, the divi was adjusted to take into account the recent splitting off of HLN. Add the two divis together and they probably add up to the pre-split gsk divi. Not 100% sure, but in any case, no one sensible would say the divi has been 'slashed', imv. If you can't stand the heat etc. Oh, you already have left the kitchen.

I think you are referring to another reader, I have not left but as a long term hold divi investor continue to retain both GSK and HLN. But the slashed divi comment was mine. I suggest you should check before referring to factual matters because I think you are wrong.

Here's why
old GSK 2021 divi 80.00p
new GSK 2022 divi 57.75p

HLN 2022 divi 2.4p

Thus the total for the two for 2022 of 60.15p is below the old GSK 80p for 2021 by 24.8%. I'd call that slashed and so you are incorrect to claim that they "probably add up to the pre-split gsk divi" or that "no one sensible would say the divi has been 'slashed', imv."

Another way to look at it, which avoids the potential distortions of the share adjustments, is not at the divis per share but to compare the total cash income received by an investor like me who continued to hold throughout the demerger, with no voluntary shareholding changes. Without a doubt my income has been "slashed".

HLN paid only the final divi for 2022 and will likely pay both an interim and final for 2023 but it remains very unlikely that even then, the total income from both for 2023 will match that from old GSK for 2021.

Your Recent History

Delayed Upgrade Clock